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Abstract
Background: The risk for major depression and obesity is increased in adolescents and adults with attention-deficit /
hyperactivity disorder (ADHD) and adolescent ADHD predicts adult depression and obesity. Non-pharmacological
interventions to treat and prevent these co-morbidities are urgently needed. Bright light therapy (BLT) improves day–
night rhythm and is an emerging therapy for major depression. Exercise intervention (EI) reduces obesity and improves
depressive symptoms. To date, no randomized controlled trial (RCT) has been performed to establish feasibility and
efficacy of these interventions targeting the prevention of co-morbid depression and obesity in ADHD. We hypothesize
that the two manualized interventions in combination with mobile health-based monitoring and reinforcement will result
in less depressive symptoms and obesity compared to treatment as usual in adolescents and young adults with ADHD.
Methods: This trial is a prospective, pilot phase-IIa, parallel-group RCT with three arms (two add-on treatment groups
[BLT, EI] and one treatment as usual [TAU] control group). The primary outcome variable is change in the Inventory of
Depressive Symptomatology total score (observer-blinded assessment) between baseline and ten weeks of intervention.
This variable is analyzed with a mixed model for repeated measures approach investigating the treatment effect with
respect to all three groups. A total of 330 participants with ADHD, aged 14 – < 30 years, will be screened at the four study
centers. To establish effect sizes, the sample size was planned at the liberal significance level of α = 0.10 (two-sided) and
the power of 1-β = 80% in order to find medium effects. Secondary outcomes measures including change in obesity,
ADHD symptoms, general psychopathology, health-related quality of life, neurocognitive function, chronotype, and
physical fitness are explored after the end of the intervention and at the 12-week follow-up.
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Discussion: This is the first pilot RCT on the use of BLT and EI in combination with mobile health-based monitoring and
reinforcement targeting the prevention of co-morbid depression and obesity in adolescents and young adults with
ADHD. If at least medium effects can be established with regard to the prevention of depressive symptoms and obesity,
a larger scale confirmatory phase-III trial may be warranted.
Trial registration: German Clinical Trials Register, DRKS00011666. Registered on 9 February 2017. ClinicalTrials.gov,
NCT03371810. Registered on 13 December 2017.
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Background
Attention-deficit / hyperactivity disorder (ADHD) is a
neurodevelopmental disorder characterized by age-
inappropriate hyperactivity, impulsivity, and inattention
with onset in early childhood and a high rate of persist-
ence into adulthood [1]. With a ~ 5% prevalence in
childhood and ~ 3% in adulthood, ADHD is among the
most common psychiatric disorders [2, 3]. Being a
prevalent neurodevelopmental disorder with childhood
onset, ADHD is also often the entry point into a trajec-
tory defined by a high risk for co-morbid conditions.
Co-morbidity is a hallmark of adult ADHD [4]: around
85% of adults with ADHD suffer from at least one co-
morbid psychiatric disorder including, most often, mood
(~ 60%), anxiety (~ 30%), substance use disorders
(~ 45%), and personality disorders (~ 35%) [5]. Children
and adolescents with ADHD are at high risk of develop-
ing these psychiatric conditions, specifically depression,
when they reach adulthood [6, 7]. Furthermore, the
prevalence of obesity, which is about 40% higher in
children and adolescents with ADHD compared to indi-
viduals without ADHD, is further increased during
adulthood (about 70% higher in adults with ADHD com-
pared with individuals without ADHD) [8–10]. Thus,
obesity—accompanied by an increased risk of metabolic
syndrome and cardiovascular disease—can be regarded as
an important somatic sequel of ADHD [11]. Co-morbid
psychiatric and somatic conditions significantly increase
disease burden leading to higher rates of detrimental out-
comes on health (i.e. more than doubling mortality rates)
and socioeconomic status [12]. Therefore, effective treat-
ments of ADHD’s co-morbid disorders, specifically de-
pression and obesity, are urgently needed. Moreover,
prevention of these co-morbid conditions during the
potentially sensitive phase of adolescence and young
adulthood [6, 13] is of upmost importance.
Stimulant medication (e.g. methylphenidate) is the
first-line pharmacologic treatment of the core symptoms
of ADHD [14]. However, their effects on co-morbid de-
pression and obesity are largely unclear due to a lack of
randomized controlled studies (RCTs). Also, the effects
of non-stimulant medication (e.g. atomoxetine) on these
co-morbid symptoms have been rarely studied [15].
With regard to depression, evidence derived from ani-
mal models suggests that early exposure to stimulants
may increase the long-term risk of depressive-like behav-
iors [16, 17]. In contrast, retrospective and prospective
clinical studies following adolescents with ADHD found
none or protective effects of stimulants on the risk of
later depression [18–22]. Stimulant medication has also
been associated with reduced rates of concurrent depres-
sion and suicide-related events in patients with ADHD
[22, 23]. In contrast, atomoxetine has not been shown to
be effective in improving co-occurring depressive symp-
toms in adolescents with ADHD [15, 24].
With regard to obesity, a meta-analysis of cross-
sectional studies found that rates of obesity were
decreased by about 40% in pharmacologically treated
patients (mainly with stimulants) compared with non-
pharmacologically treated ADHD patients [8]. However,
although an anorexigenic effect of stimulants has been re-
ported [25, 26], to our knowledge, RCTs and prospective
clinical studies targeting (1) the effects of pharmacological
ADHD treatment on disordered eating and obesity in ado-
lescents and adults with ADHD and (2) the risk for devel-
oping obesity in adulthood are lacking.
In conclusion, the available evidence for potential pro-
tective effects of pharmacological ADHD treatments on
co-occurring depressive symptoms and obesity is largely
limited in adolescents and young adults with ADHD. In
addition, non-adherence to medication typically increases
during adolescence [27–29], further complicating effective
treatment and prevention of ADHD co-morbidities during
this particularly risky developmental phase. Therefore,
alternative or adjunct non-pharmacological interventions
to treat and prevent ADHD and its co-occurring symp-
toms are needed for this population.
Only few studies have evaluated the effectiveness of
psychosocial interventions in adolescents with ADHD
taking co-morbid conditions into account. The available
evidence suggests some benefit of skills training coupled
with parent and teacher training for academic and
organizational skills, whereas effects on core ADHD as
well as on co-occurring emotional and behavioral symp-
toms have been inconsistent [30]. Manualized cognitive
behavioral therapy (CBT) combining operant (i.e. skills
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training) with cognitive strategies (i.e. cognitive restruc-
turing) is another treatment option that has been
assessed in RCTs in adolescents and adults with ADHD.
The findings of the few studies consistently reported
beneficial effects on core ADHD symptoms [31–34]
which were accompanied by additional improvements of
co-morbid symptoms, such as depressive, anxiety, and
oppositional-defiant symptoms, organizational skills, and
functional impairment [31, 32, 35]. Preliminary data sug-
gest that adolescents with co-morbid depression and
anxiety might benefit most from manualized CBT [36], a
finding that warrants further investigation.
Taken together, the development of effective pharma-
cological and non-pharmacological treatments to im-
prove and prevent co-morbid depression and obesity in
adolescents and adults with ADHD is still in its infancy.
Guidelines for treatment and prevention of co-morbid
depression and obesity in adolescents and young adults
with ADHD are not yet available. Therefore, a wider
range of treatment and prevention approaches need to
be evaluated in RCTs and these interventions should dir-
ectly target the known pathophysiological mechanisms
of ADHD and its co-morbidities. Following these goals,
the present phase-IIa trial aimed at establishing feasibil-
ity and effect sizes of two kinds of non-pharmacological
interventions—physical exercise (exercise intervention
[EI]) and bright light therapy (BLT)—in order to prevent
the development and progression of depression and
obesity in adolescents and young adults with ADHD.
Physical exercise is thought to directly modulate a dopa-
mine (DA) dysregulation [37] which has been established as
a key pathophysiological mechanism underlying ADHD but
also plays a role in mood disorders (especially in anhedonic
behavior) [38] and obesity, conceptualized as addictive food
intake [39]. Following the idea of a shared DA dysregulation
that can be modulated by physical exercise, therapeutic
effects of this intervention on ADHD symptoms and co-
morbid depression and obesity can be hypothesized.
Previously, the effectiveness of physical exercise in re-
ducing depressive symptoms has been demonstrated in
mildly and moderately depressed adults [40, 41] and ad-
olescents [42]. It is also known that physical exercise
and higher cardiorespiratory fitness attenuates the health
risks of obesity [43, 44]. Physical exercise interventions
have been successfully implemented in programs to pre-
vent obesity in children [45, 46] and have been shown to
effectively reduce weight in overweight and obese adults
and adolescents [47, 48]. Moreover, physical fitness has
been associated with improved cognitive function [49].
With regard to ADHD, some evidence suggests that
physical exercise improves neurocognitive function in
children with ADHD [50], and therefore has been dis-
cussed as a potential protective factor for ADHD [51].
Specifically, physical exercise may release DA in the
brain, improving attention and cognition [52, 53], and
therefore it may be used to regulate hyperactivity as well
as inattentive symptoms in people with ADHD [54, 55].
These previous findings strongly suggest that physical
exercise bears the potential of improving and/or pre-
venting the core symptoms of ADHD; however, its
effects on obesity and depression await systematic inves-
tigation in patients with ADHD [56].
BLT is thought to modulate the circadian (CIRCA)
system dysfunctions [57, 58]—another key pathophysio-
logical mechanism possibly linking ADHD to co-morbid
symptoms of depression and obesity [59–62]. Following
the idea of a shared CIRCA dysregulation possibly asso-
ciated with the striatal dopaminergic system [63] that
can be modulated by BLT, therapeutic effects of this
intervention on ADHD symptoms as well as co-morbid
depression and obesity can be expected.
In ADHD, circadian system dysfunctions are indicated
by phase delays in the sleep/wake cycle with changes in
diurnal preference towards greater eveningness, noctur-
nal rise in melatonin, and early morning increase in
cortisol [57, 58, 64, 65]. Physiologically, when adminis-
tered in the early morning, BLT suppresses the night-
time melatonin production [66] and decreases the
cortisol levels that usually peak after waking up [57].
Hence, with morning light administration, the wake-
time can be shifted to an earlier time (phase advance)
and circadian rhythms can be stabilized [67]. BLT has
been shown to be efficacious for the treatment of sea-
sonal and non-seasonal depression in adults and adoles-
cents [68–71], whereas findings on the prevention of
seasonal affective disorder have been inconclusive [72].
Accumulating evidence also suggests its efficacy in eat-
ing disorders and obesity [73]. In patients with ADHD, a
recent study demonstrated that morning BLT advanced
sleep timing which was associated with decreased
ADHD symptoms, specifically hyperactivity and impul-
sivity [74]. One open-label trial also examined the poten-
tial of BLT on improving co-morbid depressive
symptoms [75]. Three weeks of morning BLT advanced
the circadian phase in ADHD adults as measured by a
questionnaire and led to significant reductions in both
subjective and objective measures of core ADHD symp-
toms as well as depressive symptoms. Together, these
findings suggest that chronobiological therapies bear
substantial innovation potential, but RCTs are needed to
systematically test their feasibility and effectiveness on
improving ADHD and co-morbid depression and obesity
in adolescents and young adults.
Importantly, targeting adolescents and young adults
with these interventions implies specific problems, as this
age group usually has little motivation for lifestyle change.
Therefore, the PROUD trial will make use of cutting edge
mobile technology, which is generally viewed very
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favorably by this age group, assuming that this might
booster motivation. Both interventions will be supported
by a mobile health (m-health) application that monitors
physical exercise, light exposure, and related parameters
and feeds them back to the user to improve motivation
for change. A recent meta-analysis has concluded
that reinforcement-based exercise interventions using
m-health approaches improve effects on weight loss in
obesity [76]. Although commercial apps for mental disor-
ders which have no empirical evidence are omnipresent,
scientific studies using m-health applications as a tool to
monitor and reinforce interventions in mental disorders,
specifically ADHD, are largely lacking [54, 77].
In conclusion, the aim of the present multicenter,
prospective, pilot, observer-blinded, parallel-group
(allocation ratio 1:1:1), phase-IIa RCT is to establish
feasibility and effect sizes of two add-on ten-week inter-
ventions—EI and BLT in combination with m-Health-
based reinforcement—targeting the prevention of the de-
velopment and progression of co-morbid depression and
obesity in adolescents and young adults aged 14 – < 30
years with ADHD. Both interventions are risk-free, cost-
effective, easy-to-use, and portable, and therefore can be
easily implemented in the daily life of adolescents and
young adults. If at least medium effects can be estab-
lished with regard to the prevention of depressive symp-
toms and obesity, a larger scale confirmatory phase-III
trial may be warranted.
It is hypothesized that the two manualized ten-week in-
terventions will result in a smaller increase of depressive
symptoms and obesity compared to a treatment as usual
(TAU) control condition. In addition, pre-existing depres-
sive symptoms and obesity are expected to decrease after
ten weeks of either BLT or EI compared to TAU. TAU in-
cludes ten weeks of stable pharmacotherapy, group-based
or individual CBT (not including elements of BLT or EI).
To assess the stability of these secondary prevention ef-
fects, follow-up assessment will be done 12 weeks after
the end of the intervention. Furthermore, immediate and
long-term intervention effects on core ADHD symptoms,
general psychopathological symptoms, health-related
quality of life, neurocognitive function, chronotype, body-
related measures such as blood pressure and heart rate,
physical fitness, and hormone concentrations will be
assessed. Variables possibly moderating treatment effect,
including age, sex, medication, physical fitness and activ-
ity, daily light exposure, chronotype, and mood regulation
will be explored as well as variables possibly mediating
treatment effects, such as reward processing, stress re-
activity, and compliance with the intervention.
Methods
This protocol is presented in accordance with the 2013
SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) Statement (See Additional file 1
for the populated SPIRIT Checklist) [78].
Study setting
The trial is performed by close cooperation of four large
European clinical centers: Goethe University Hospital
Frankfurt, Germany (Department of Child and Adoles-
cent Psychiatry, Psychosomatics and Psychotherapy, and
Department of Psychiatry, Psychosomatic Medicine and
Psychotherapy); Radboud University Medical Centre,
Nijmegen, The Netherlands (Karakter Child and Adoles-
cent Psychiatry, and Department of Psychiatry); Vall
d’Hebron Research Institute (Group of Psychiatry,
Mental Health and Addiction), Barcelona, Catalonia,
Spain; and Institute of Psychiatry, Psychology and
Neuroscience, King’s College London (Social, Genetic
and Developmental Psychiatry Centre), UK.
Eligibility criteria
Participants’ inclusion and exclusion criteria are listed in
Table 1. All participants must be aged 14 – < 30 years,
meet DSM-5 criteria for a lifetime history of childhood
onset ADHD as well as current ADHD criteria estab-
lished by a specialist in the field, and show an
intelligence quotient (IQ) ≥ 75. TAU will be allowed in
all groups. TAU includes stable psychopharmacotherapy
for ADHD (stimulant and non-stimulant medication),
stable medication for chronic medical conditions not
interfering with interventions, individual or group-based
psychotherapy or family support. With regard to co-
morbid psychiatric disorders, participants with any
severe psychiatric disorder (especially bipolar disorder,
schizophrenia, autism spectrum disorder, schizoaffective
disorder, organic psychiatric disorder [current or life-
time], borderline personality and substance use disorder
or dependency) other than the co-morbid conditions
explicitly studied, or patients requiring additional psy-
chopharmacotherapy or psychiatric intervention, includ-
ing day-care/inpatient treatment at start of the study, are
excluded. With regard to co-morbid medical and neuro-
logical conditions, it is essential that participants have
no severe condition interfering with or not allowing
either BLT (e.g. diagnosed eye condition or other dis-
eases with effects on the retina such as Diabetes melli-
tus, or recent eye surgery) or EI (e.g. heart disease, high
blood pressure, injuries). Also, participants are not
allowed to use antipsychotic, antiepileptic, or photo-
sensitizing medication. Only a single participation in the
trial is allowed.
Interventions
BLT
Light therapy consists of a daily (except Sunday) 30-min
exposure of white light without ultraviolet (UV)
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components in the morning or evening for ten weeks in
total provided by special 10,000 lx light boxes that
supply broadband, UV-filtered light, specifically designed
for BLT (Philips EnergyLight HF 3419). The exact time
of day of implementation (either during the morning be-
tween 06:00 and 08:00 am or the evening between 06:00
and 08:00 pm and) is determined by the type of chrono-
type (morning or evening type) of each study participant
determined by the Morningness–Eveningness Question-
naire (MEQ) [79]. The light therapy device is handed
over by trained psychologists or psychiatrists along with
an introduction to the operation and how to carry out
the light therapy at home. When receiving light therapy,
participants sit approximately 50–75 cm from the light
box, facing the illumination and glancing at the light oc-
casionally. Participants are encouraged to read, watch
TV, or work on a computer while the bright light is di-
rected at their eyes. Monitoring and feedback is realized
with the m-health system comprising a smartphone
(Motorola Moto G3) equipped with the BLT app (movi-
sensXS software, movisens GmbH, 2016) and an activity
sensor (LightMove 3 wrist, movisens GmbH, 2016,
Fig. 1) equipped with a light sensor to monitor the light
exposure of the participant. Participants wear the Light-
Move 3 wrist daily (24 h). Participants are introduced to
the usage of the m-health app by trained psychologists
or psychiatrists and a user’s guide is handed over. The
m-health app allows monitoring when participants start
and stop daily BLT; in addition, the BLT is monitored by
the light sensor. The m-health app also sends an acous-
tic signal to remind participants of their BLT and
provide them with individual feedback every day.
Physicians or therapists will not receive this feedback.
Therapists will assess participants’ compliance based on
interviews at T3.
EI
In developing the exercise manual and learning videos,
we followed the internationally accepted physical activity
guidelines [80]. These guidelines are based on a system-
atic review of > 2000 references and are the basic plat-
form for designing any exercise intervention. In
accordance with the guidelines, most of the time during
the exercise sessions is spent in aerobic exercise of
moderate-to-vigorous intensity and strength activities.
The physical exercise intervention consists in training
three days a week for ten weeks. Participants will per-
form three days of proposed aerobic activities and on
two of these days they will also do muscle-strengthening
exercises. Specifically, a training day consists of: (1) a 5-
min warm-up period; (2) 10–35 min of muscle-strength
training on two of the three days; (3) 20–40 min of
aerobic training; and (4) 5 min of flexibility/stretching
cool-down. During the course of the ten weeks, the dur-
ation and intensity of the exercises increases gradually
by combining number of exercises, repetitions, rests,
and frequency.
(1) The warm-up consists of doing an activity at a slower
speed or lower intensity. A warm-up before moderate or
vigorous intensity aerobic activity allows a gradual increase
in heart rate and breathing at the start of the episode of ac-
tivity. Warm-up includes light walking and joint
mobilization of the upper (neck, shoulders) and lower limbs
(hips, knees, and ankles). (2) The muscle-strength training
Table 1 Inclusion and exclusion criteria of the PROUD trial
Inclusion
criteria
All participants must meet DSM-5 criteria for a lifetime history
of childhood onset ADHD (DSM-5 314.00, 314.01) as well as
current ADHD criteria established by a specialist in the field
Age 14 – < 30 years
Written informed consent of the legal caretakers of the
participant (age < 18 years) and, if possible, written assent of
the participant (age < 18 years) himself
Written informed consent of the of the participant
(age ≥ 18 years)
Stable TAU comprising pharmacotherapy, group-based or
individual CBT (not including elements of BLT or EI)
Normal or corrected to normal vision
Ability to understand, read, write, and speak fluently in the
language of the study site
Ability to regularly and reliably attend appointments
Exclusion
criteria
IQ < 75 (measured by WAIS-IV or WISC-IV vocabulary and
matrix reasoning subtests)
Any severe co-morbid psychiatric disorder other than the
co-morbid conditions explicitly studied with necessary
additional psychopharmacotherapy or psychiatric
intervention involving day-care/inpatient treatment at start
of study, especially a diagnosis of bipolar disorder,
schizophrenia, autism spectrum disorder, schizoaffective
disorder or organic psychiatric disorder (current or lifetime)
Any severe medical or neurological condition interfering with
interventions
Any severe medical or neurological condition not allowing
BLT or EI
Use of antipsychotic or anti-epileptic medication, photo-
sensitizing medication (e.g. lithium, St. John’s Wort)
Substance use disorder (DSM-5) or dependency (DSM-5)
History of epilepsy
Acute suicidal ideation
Pregnancy
Participant is related to the investigator or study staff
Participation in other clinical trials and observation period
of competing trials (participation in other studies is permitted
if the respective study is a no-medication or psychotherapy
trial and if its aims do not interfere with the aims of the
present study)
No participant will be allowed to enroll in this trial more than
once
WAIS Wechsler Adult Intelligence Scale, WISC Wechsler Intelligence Scale for
Children, IQ intelligence quotient, CBT cognitive behavioral therapy
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includes whole-body exercises, which incorporate push-
ups, front plank, lunge, chair squat, hip thrust, etc. (3)
Aerobic activities are physical activities in which people
move their large muscles in a rhythmic manner for a
sustained period. Aerobic activity makes a person’s
heart beat more rapidly to meet the demands of the
body’s movement. Running, brisk walking, bicycling,
playing basketball, dancing, and swimming are all ex-
amples of aerobic activities. (4) A cool-down after activ-
ity allows a gradual decrease at the end of the episode.
The cool-down period includes breathing, stretching,
and relaxing exercises.
The participants can decide which days of the week
they want to perform the physical exercises. Participants
are recommended to complete training sessions sepa-
rated by 48-h rest periods whenever possible. Not all
participants will have the same fitness level at the begin-
ning of the intervention. Consequently, and in order to
ensure compliance by all participants, we prescribe three
physical exercise programs of differing intensity based
on the participant’s baseline cardiorespiratory fitness. In
particular, we use the Chester Step Test, which is in-
cluded in the pre-test measurements for that task, to as-
sess the baseline cardiorespiratory fitness level. The
Chester Step Test can predict maximal oxygen uptake
(VO2max). Based on the value obtained in the Chester
Step Test, participants are allocated to one of the three
exercises programs (light, moderate, or high intensity).
All three exercise programs have the same warm-up and
cool-down exercises. The participants do the same exer-
cise program proposed at baseline during the ten-week
intervention.
Instruction, monitoring, and feedback are realized by
the m-health system including a smartphone (Motorola
Moto G3) equipped with the m-health app (movisensXS
software, movisens GmbH, 2016), SD cards to store the
exercise videos, as well as an activity sensor (LightMove
3 wrist, movisens GmbH, 2016) equipped with a mobile
sensor for the acquisition of physical activity (LightMove
3 wrist, movisens GmbH, 2016, Fig. 1). The sensor is
equipped with a Bluetooth Smart interface and offers the
possibility of doing online analysis of data on the sensor.
The sensor records the raw data of three-dimensional (3D)
acceleration, barometric air pressure, and temperature.
From these data, secondary parameters such as activity
class, body position, steps, energy expenditure, and meta-
bolic equivalents can be calculated with the movisens
DataAnalyzer software. The sensor can be fixed with a
band at the wrist. Participants are asked to wear the sensor
daily (24 h) during the ten-week intervention period. Par-
ticipants are introduced to the usage of the m-Health app
by trained psychologists or psychiatrists and a user’s guide
is handed over.
Strengthening exercises are presented in the form of
video sessions on the smartphones which are executed
while watching the videos. The videos present an
exercise specialist who carries out the different physical
exercises proposed and subtitles showing graphical de-
scription, intensity, and rest of each exercise. The
m-health app also allows monitoring when participants
start and stop their aerobic and strengthening exercises;
in addition, the EI is monitored by the activity sensor.
Acoustic signals to remind participants of their EI as
well as individual feedback (a reward summary including
information on duration of the excises, movement accel-
eration intensity, and number of steps accompanied by a
motivational message) are provided by the m-health app
at the end of each day. Physicians or therapists will not
receive this feedback. Therapists will assess participants’
compliance based on interviews at T3.
Fig. 1 M-Health system consisting of the smartphone and the sensor (adapted with permission of movisens). Example from the EI intervention.
The “home screen” of the movisensXS app shows four different buttons: (1) Goal of the week; (2) Learn about the exercises; (3) Start exercise; (4)
Feedback. If participants press button three (Start exercise), the exercise videos are played
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Criteria for discontinuing allocated interventions for a given
trial participant
Generally, both, BLT and EI, are considered as safe inter-
ventions with no specific, relevant risk conferred to the
trial participants. The BLT device implemented in this
study (Chronolux Medic-4) uses UV and infrared (IR)
filtered therapeutic light (10,000 lx) and is thus safe for
the eyes and skin. If side effects occur (e.g. nausea, head-
ache, eyestrain), they are usually mild and short-lived
[81]. In rare circumstances, BLT can trigger a manic epi-
sode in bipolar disorder, which is therefore an exclusion
criterion [81]. Regarding the EI arm of the intervention,
it should be said that the risks associated with exercise
are directly related to the “dose” of exercise and top ath-
letes are at a high risk of suffering different types of in-
juries. However, in this study, the exercise administered
will be recreational and only small injuries (e.g. ankle
sprain) might occur with a comparable probability to
school recess (in the case of adolescent participants) or
in any daily activity. If any undesirable effect occurs, this
will be reported as an adverse event (AE) and reported
to the local primary investigator and to the principal in-
vestigator (PI) who will decide about withdrawal of par-
ticipants from the clinical trial (see Additional file 2). All
ongoing AEs/serious adverse events (SAEs) of withdrawn
participants will be followed up until no more signs and
symptoms are verifiable or the participant is in a stable
condition or the participant has taken back his/her ap-
proval for medical follow-up.
Strategies to improve adherence to intervention protocols
and any procedures for monitoring adherence
To ensure comparability of the BLT and EI interventions
between the four different centers, detailed manuals
have been developed that: provide a standardized
psycho-education element to explain the basic elements
of the respective therapy and its mode of action; detail
the frequency and duration of the respective therapy;
detail the m-health-based electronic monitoring,
reinforcement, and coaching part; and provide the clin-
ical therapist with standardized motivational interview-
ing skills to improve participants’ compliance with the
intervention. Participants’ compliance with the interven-
tion (BLT and EI) is monitored with the m-health app
and the light and activity sensor throughout the ten
weeks of intervention. Therapists have no access to this
information but will assess participants’ compliance
based on interviews at T3.
Relevant concomitant care and interventions that are
permitted or prohibited during the trial
Psychotropic medication is started or changed at least
four weeks before randomization and needs to remain
stable (mg/kg body weight) throughout the intervention
and the three-month follow-up of the study (with the
exception of dose adjustment to body weight changes).
The following psychotropic medication is allowed as sin-
gle or combined treatment: any ADHD-specific medica-
tion, antidepressive treatment, and low dose neuroleptic
treatment to control aggressive behavior or mood
swings. In addition, stable medication for the treatment
of chronic conditions as allergies, asthma, enuresis,
sleeping problems, and intermitting medication for acute
infections or pain is allowed. Pharmacological treatment
is documented at each time of assessment (T1–T5, see
Fig. 3) and psychotropic medication effects on treatment
outcome will be explored in analyzing study outcomes.
Any individual-based (e.g. CBT that does not include el-
ements of BLT and EI, school-based intervention, occu-
pational, language, psychomotor therapy) as well as
family-based intervention is allowed. Any additional
treatment is documented exactly (kind of intervention,
frequency, etc.). The following concomitant treatments
are not permitted during the trial: additional EI and add-
itional BLT. Relevant additional treatments administered
to the participants on entry to the trial or at any time
during the trial are regarded as concomitant treatments
and are documented on the appropriate pages of the
case report form (CRF).
Outcome measures
The primary outcome measure is the change in the
clinician-rated Inventory of Depressive Symptomatology
(IDS-C30) [82] total score (observer-blinded assessment)
between baseline (T2) and after the end of the interven-
tion (T4, primary endpoint, see Fig. 3). The IDS-C30
rating includes all DSM-5 diagnostic criterion items for
major depressive disorder (e.g. mood, vegetative, psycho-
motor, and cognitive symptoms) as well as commonly
associated symptoms such as anxiety, irritability, melan-
cholic, and atypical symptom features to assess the
severity of depressive symptoms over the last seven days.
Items are rated on a 4-point Likert scale based on the
information obtained during a semi-structured inter-
view. The total score range is 0–84. The psychometric
properties of the IDS-C30 and its sensitivity to change
with interventions have been well established in different
study samples and RCTs [82–84]. Parallel versions exist
in English, German, Spanish, and Dutch. The IDS is
under investigation in adolescent patients; however, a
standardization for individuals aged 14–17 years is still
lacking. Because changes in raw scores are assessed in
this study, the IDS-C30 is considered a valid measure in
adolescents.
The secondary outcome measures aim to assess inter-
vention effects on depressive symptoms at the 12-week
follow-up (T5) and to differentially assess changes in
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obesity, health-related quality of life, ADHD symptoms,
general psychopathology, chronotype, neurocognitive
function, body-related measures, and physical fitness be-
tween baseline (T2), the end of intervention/ TAU (T4),
and 12-week follow-up (T5). In addition, secondary
outcome measures include several parameters measured
with the m-health app between the one-week baseline
and one-week post-intervention assessment. Also, hor-
mone concentrations will be assessed in a Frankfurt
subsample at T2 and T4. All scales and questionnaires
as well as physical fitness tests and neurocognitive tests
have been frequently used in clinical and non-clinical re-
search and have been validated in adults and mostly also
in adolescents (see Additional file 3). For all assessments,
parallel versions exist in the languages of the four study
sites. Secondary outcome measures are described in de-
tail in Additional file 3.
Participant timeline
The trial time flow is shown in Figs. 2 and 3. At T1, the
diagnosis of ADHD is established by performing struc-
tured clinical interviews. The Kiddie-Schedule for
Affective Disorders and Schizophrenia - Present and
Lifetime Version (K-SADS-PL) [85] is used to assess
ADHD symptoms and co-morbid conditions in adoles-
cents. To obtain as much information as possible for
high valid diagnoses, both with regard to externalizing
and internalizing conditions, the K-SADS-PL will be
conducted separately with the adolescent and at least
one primary caregiver. For the final rating, the trained
clinician will take both sources of information into ac-
count. In adults, the Diagnostic Interview for ADHD in
adults (DIVA) [86] is administered to assess ADHD
symptoms and the Structured Clinical Interview for
DSM-IV Axis I and II Disorders (SCID-I and II) [87] to
Fig. 2 Trial time flow. T, time-point; I, intervention; EI, exercise intervention; BLT, bright light therapy; TAU, treatment as usual
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assess co-morbid conditions. The Adult ADHD Self-Re-
port Scale (ASRS) [88] and the Wender-Reimherr Adult
ADHD Symptom Rating Scale (WRAADDS) [89] are
used to substantiate diagnosis. All interviews and ques-
tionnaires will be adjusted to DSM-5 criteria. After hav-
ing established the diagnosis of ADHD and having
completed screening for eligibility based on interviews/
questionnaires (Alcohol Use Identification Test [AUDIT]
[90], National Institute on Drug Abuse [NIDA] Quick
Screen [91], Physical Activity Readiness Questionnaire
[PAR-Q] [92], physical examination, and IQ tests
[Wechsler Adult Intelligence Scale, WAIS-IV [93]/
Wechsler Intelligence Scale for Children, WISC-IV [94]],
informed consent is obtained. Trial-specific assessments
are done at T1 after informed consent has been obtained
and m-health will be introduced to participants and their
parents (if applicable) (T1, duration = approximately 5 h
for adults and 3.5 h for children/parents including
breaks). Within two weeks after T1, the one-week base-
line assessment with the m-Health system takes place at
home. During this week, participants will wear the light
and movement sensors on two working days and on
Saturday and Sunday (always 24 h) and they will be
asked to answer questionnaires (regarding mood regula-
tion, reward and stress reactivity, sleep behavior, inatten-
tion, and context) 12 times a day (duration = 1 min
each) provided by the m-health app. A subset of adult
participants from Frankfurt are also asked to collect
saliva on one day of the one-week period at home ten
times over 24 h (immediately after awakening:
approximately at 07:00, 30 min after wakening: approxi-
mately at 7:30 am, 11.00 am, 6.00 pm, 7.00 pm, 8.00 pm,
9.00 pm, 10.00 pm, midnight, 1.00 am) by chewing on a
cotton swab which will be stored in tubes (Salivette™,
Sarstedt, Germany). All participants are asked to fill out
several questionnaires on the last day of the one-week
period (duration = approximately 1 h) and to bring them
along at T2. Baseline assessment based on interviews,
questionnaires, body parameters/ fitness tests, and neuro-
cognitive tests will be finished at T2 (duration = approxi-
mately 4 h for adults and children/parents including
breaks) which is scheduled within three weeks after T1
and within one working week after the one-week
m-health baseline assessment. Thus, all primary and
secondary outcome measures are obtained either at T1,
T2, or during the one-week baseline assessment. The
randomization takes place at T2. Participants will be
instructed in how to use the m-health app for the respect-
ive therapy and they will be introduced to all devices. Ex-
perimental groups will begin with the interventions the
next day, while the control group continues with TAU
which lasts for ten weeks. One week after T2, participants
will be contacted via email to administer the Rey Auditory
Verbal Learning Test (RAVLT) [95] recognition subtest
Fig. 3 Schedule of enrolment, interventions, and assessments at the
different time-points (T1–T5)
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(by sending a link via email to an online survey, 10 min).
T3 (mid-intervention assessment) will take place five
weeks after T2 (± 3 days). This mid-intervention assess-
ment aims at obtaining the primary and secondary out-
come measures during the ongoing trial to get some
information on participants dropping out from the study
before T4 (duration of T3 = approximately 3 h for adults
and children/parents including breaks). Experimental
groups will continue with the interventions for another
five weeks while the control group continues with TAU.
After ten weeks of intervention or TAU (control group)
(five weeks after T3 ± 3 days), primary and secondary out-
come measures are assessed again (duration = approxi-
mately 4 h for adults and children/parents including
breaks), followed by a one-week post-intervention assess-
ment with the m-health system including the same pa-
rameters as during the baseline m-health assessment.
Saliva will be taken during one day of the one-week period
(using the same procedure as during the baseline assess-
ment) in the Frankfurt subgroup. One week after T4, par-
ticipants will be contacted via email to administer the
RAVLT recognition subtest. To assess the stability of the
therapy effects, the study also includes a follow-up (T5)
assessment 12–14 weeks after T4 (T5, duration = approxi-
mately 4 h for adults and children/parents including
breaks). One week after T5, participants will be contacted
via email to administer the RAVLT recognition subtest.
Sample size calculation
The sample size calculation refers to the primary end-
point, more precisely, the expected change in the
clinician-rated observer-blinded IDS-C30 total score
between T2 and T4 in the intention-to-treat (ITT)
population. The sample size calculation is based on
the expectation to find a clinically relevant medium ef-
fect size (d = 0.5) with a two-sample t-test of at least
one of the two interventions compared to TAU on the
primary endpoint. As this is a pilot study to establish
effect sizes, the sample size is planned at the liberal
significance level of α = 0.10 (two-sided) and the
power of 1-β = 80%. Taking into consideration the
three-group design and an expected drop-out rate of
about 30%, n = 219 participants will be allocated and
analyzed. Based on the information received from the
clinical study centers, it is expected that about 25–
35% of the screened participants cannot be included in
the study due to violation of inclusion/exclusion cri-
teria. Hence, n = 330 participants will be assessed for
eligibility. It can be expected that application of an
analysis of covariance in the evaluation will reduce the
standard deviation thus increasing the actual power of
the study. Sample size calculation was done using
ADDPLAN v6.1 [96].
Recruitment
Recruitment and treatment of participants will be pro-
vided at four trial centers, each enrolling 55 participants.
King’s College is affiliated with a number of National
Health Service foundation trusts across England. The
other clinical centers are affiliated or part of University
Hospitals and have large outpatient units specialized in
ADHD diagnosis and treatment across the life-span, so
that the planned recruitment numbers are feasible.
Participants are recruited by flyers, public notices, and
personal contact from inpatient and outpatient depart-
ments of the participating sites, as well as by public an-
nouncements, press releases, newspaper advertisements,
and Internet/social media campaigns. Measures are in
place to mitigate risk in the case of under-recruitment:
reimbursement to individual centers will be done in the
form of case payment, as stipulated in an agreement
before beginning of the trial; pre-financing is carried out
on an annual basis. In the case of a participating site
falling short of the recruitment plan, the CoCA (EU
project Comorbid Conditions of Attention deficit /
hyperactivity disorders) steering committee, advised by
an independent Data Safety and Monitoring Board
(DSMB, see below), reserves the right to stop study par-
ticipation for this site and either increase recruitment
numbers at the remaining sites or include a new recruit-
ment site.
Assignment of interventions
After written informed consent, participants are succes-
sively randomized to one of the three groups (BLT, EI,
TAU). At each center, the trial coordinator generates the
randomization code using a centralized web-based tool
[97] which will be done at T2 after all baseline measure-
ments have been completed in order to ensure allocation
concealment. Randomization is a block randomization
per center and is done in an allocation ratio of 1:1:1 with
fixed block length and stratified for each participating
center. The randomization list will be kept in safe and
confidential custody at the Institute of Medical Biometry
and Informatics (IMBI). Participants withdrawn from
the trial will retain their identification codes (e.g. screen-
ing number, if already given). New participants must
always be allocated a new identification code. As the
proposed study is a non-pharmacological therapy inter-
vention study, blinding of participants as well as
therapists is not possible. However, the design is
observer-blinded. Clinicians, who assess the primary
outcome measure, the IDS-C30 total score, and the
ADHD Rating Scale total score, are blind to treatment
allocation. Therefore, at each site, randomization will be
done only by the trial coordinator who is also the only
person who will manage the investigator site file (ISF).
Clinicians are not involved in the randomization
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procedure and are not allowed to receive information
about group assignment. Clinicians will be provided with
data recording sheets and data will be entered into the
CRF by the trial coordinator. In addition, participants are
instructed not to talk about their intervention at each visit.
Adherence to randomization is monitored by an inde-
pendent clinical on-site monitor, the Coordination Centre
for Clinical Trials (KKS), University Hospital Heidelberg.
Data collection methods
Training plans
Group training sessions for all psychologists/psychia-
trists involved in the trial from all centers took place at
several consortium and kick-off meetings before the trial
start. Trainings covered study requirements (e.g.
observer-blinded assessment of the primary outcome
measure), general information about obtaining research
quality data, and recording data (e.g. discussing data
collection forms in detail on an item-by-item basis).
Data collection forms and the standard operating proce-
dures (SOPs) can be downloaded from the CoCA intra-
net. The data to be collected and the procedures to be
conducted at each visit will be reviewed in detail (see
data management and monitoring). Furthermore, inter-
vention manuals were discussed in detail at previous
meetings and phone conferences. At subsequent CoCA
consortium meetings and during regular monthly phone
conferences, clinicians will be monitored with regard to
the correct implementation of the manuals and evolving
questions can be discussed and solved. The training
sessions also included training of the standardized pro-
cedures to assess primary and secondary outcome mea-
sures. Reliability training of the primary outcome
measure will be continued locally following a standard
procedure and inter-rater reliability will be assessed
during the course of the trial.
Participant retention
Once a participant is enrolled or randomized, the study
site will make every reasonable effort to follow the partici-
pant for the entire study period. Study site staff are re-
sponsible for developing and implementing local SOPs to
achieve a low rate of loss to follow-up (e.g. reminding par-
ticipants and parents of the upcoming visits via phone call
or email, motivational interviews during visits, etc.).
Participant withdrawal
Participants may either withdraw themselves from the
intervention, but will stay in the study (I) or the partici-
pants may totally withdraw from the trial (II). A third op-
tion is that, due to SAEs or other events, the PI decides
that the participant has to withdraw from the study.
(1) Participants withdrawing at their own request or at
request of their legal representative: participants and
their legal representatives are allowed to withdraw
their consent to participate in the study and the
study interventions at any time. The data which
were collected before the withdrawal will be used in
the statistical analysis.
(2) If an individual or the legal representative totally
withdraws from the trial and requests the extinction
of data, the data cannot be included in the statistical
analysis and will be erased from the database.
(3) The PI or the local primary investigator needs to
decide on the participant’s study withdrawal in the
following situations: (i) if, in the principal or primary
investigator’s opinion, continuation of the treatment
would be detrimental to the participant’s wellbeing;
(ii) with admission into a psychiatric hospital; (iii)
new occurrence of exclusion criteria under the
condition that the security of the participant is
thereby endangered. A change in pharmacotherapy
is no criterion for withdrawal from the trial. The
principal or the local primary investigator decides
about withdrawal of participants from the clinical
trial or from the investigation in case of occurrence
of the criteria mentioned above.
A very low frequency of AEs/SAEs can be expected for
BLT and EI. Nevertheless, a DSMB will be installed and
safety-relevant events will be reported to this board.
Based on the recommendations of the DSMB, the study
might be stopped. In all cases, the reason for withdrawal
will be recorded in the CRF and in the participant’s med-
ical records. In case of withdrawal of an individual at
his/her own request, as far as possible the reason will be
asked for as extensively as possible, and documented.
Data management
The IMBI Heidelberg is responsible for data manage-
ment comprising all tasks concerning acquisition, pro-
cessing, and utilization of data with the aim of
guaranteeing high quality of the data and providing a
valid data basis for the statistical analysis. The system
used for data management is validated.
Data collection and transmission
Questionnaire, test, and interview data as well as body
and fitness parameters will be sent regularly to the IMBI
Heidelberg for data entry.
The m-health sensor data will be sent via “FileZilla –
The free FTP solution” from all clinical sites to the
Karlsruhe Institute of Technology (KIT) and from the
KIT to the IMBI Heidelberg by an AES-256 encryption.
Therefore, all clinical sites will get their own protected
and secure access to save and transfer data. Only the
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respective clinical site and the KIT will have the author-
ity to enter this access. Afterwards, the data will be
transferred to the IMBI Heidelberg in the same pro-
tected way. In this case, only the KIT and the IMBI
Heidelberg will have the authority to enter this access.
Data are stored with pseudonyms only to protect partici-
pants. The security of the service is constantly checked
by a security scan. The servers are hosted in a secure,
ISO 27001 certified environment (datadock Strasbourg).
The app data on the smartphone is also encrypted (256
Bit). If a device gets lost, remote reset is possible. All com-
munication to the web console is highly encrypted with
SSL. The data are decrypted as soon as it is in the secure
web console. The security of the service is constantly
checked by a security scan. The servers are hosted in a se-
cure, ISO 27001 certified environment. Data are stored
with pseudonyms only to protect participants. The app
data will be transferred from KIT to Heidelberg (IMBI) via
“FileZilla” by an AES-256 encryption as well.
Participants are asked to place saliva samples in the
freezer or deep-freezer compartment of their fridge and
to bring them to the clinic at T2. Saliva samples will be
centrifuged, frozen at − 20 °C, stored at the Department
of Psychiatry, Psychosomatic Medicine and Psychother-
apy, Goethe University, and sent for further analyses and
storage to the Department of Psychiatry at University of
Rostock. Saliva samples are transferred and stored with
pseudonyms only to protect participants.
All findings including clinical data will be documented
in the participant’s medical record and in the CRF. The
investigator is responsible for ensuring that all sections
of the CRF are completed correctly and that entries can
be verified against source data (exception: questionnaire
data are regarded as source data and part of the CRF at
the same time). Any errors should have a single line
drawn through them so that the original entry remains
legible and the correct data should be entered at the side
with the investigator’s signature, date, and reason for
change. Self-explanatory corrections need not to be jus-
tified. The completed CRF must be reviewed and signed
by the investigator named in the trial protocol or by a
designated sub-investigator. The original CRF will be
transferred to the data management of the IMBI within
three weeks after each participant trial visit (T2–T5);
one copy will remain with the investigator at the re-
spective clinical sites.
Data handling
In order to ensure that the database reproduces the
CRFs correctly, the IMBI accomplishes a double entry of
data (with the exception of free text) performed by two
different persons. The completeness, validity, and plausi-
bility of data are examined by validation programs,
which thereby generate queries. The checks to be
programmed will be specified beforehand in a data valid-
ation plan. The investigator or the designated represen-
tatives are obliged to clarify or explain the queries. Any
entry and correction in the study database will be re-
ported automatically in an audit file. If no further
corrections are to be made in the database, it will be
closed (removal of write access) and used for statistical
analysis. All data management activities will be done ac-
cording to the current SOPs of the IMBI.
Storage and archiving of data
The database server of the IMBI Heidelberg with the
stored data is located in a secure environment and pro-
tected by a firewall. During the trial, the data access is
restricted to data entry staff and the data manager re-
sponsible for the trial. After database closure, the bio-
metrician responsible for the trial gets access to the data
for analysis. Backups are performed regularly.
The local investigators will archive all trial data
(participant identification code list, source data, and in-
vestigator’s file) and relevant correspondence in the ISF.
The ISF is kept at each study site. Separate ISFs will be
provided for different adolescent and adult departments
at the Goethe University, Frankfurt. At all other clinical
sites, trial data for adolescents and young adults will be
archived in one ISF. The ISF, all source data, and all doc-
uments indicated in section 8 of the ICH Consolidated
Guideline on good clinical practice (GCP) (as applicable
for the present study) will be archived after finalization
of the trial according to the local legal regulations, at
least for ten years. At the end of the trial, the PI will re-
tain the originals of all CRFs. Trial-related documents
will be archived locally. The trial master file will be ar-
chived at the Department of Child and Adolescent
Psychiatry, Psychosomatics and Psychotherapy, Goethe
University Hospital.
Statistical methods
Primary outcome
Statistical methods are used to assess the quality of data,
the homogeneity of the treatment groups, the efficacy
endpoints, and the safety of the three treatment groups.
The confirmatory analysis of the primary endpoint will
be conducted on the basis of the ITT population. An
additional analysis will be conducted for the per-
protocol (PP) population that includes all participants
without major protocol violations.
A closed testing procedure will be applied control-
ling the overall type I error rate at 0.05 (two-sided).
A mixed model for repeated measures (MMRM)
approach investigating the treatment effect with re-
spect to all three intervention groups will be used.
Two-group comparisons I-1 vs TAU, I-2 vs TAU, and
I-1 vs I-2 based on contrasts will follow. Baseline
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IDS-C30, age, IQ, sex, treatment, and center will be
included as covariates. The MMRM approach models
jointly all actual observations without imputing miss-
ing data but using the within-participant correlation
structure to provide information about unobserved
post-baseline primary endpoints. Gender effects are of
particular interest. If there are not enough events per
category for the different covariates, gender effects
will be excluded from the MMRM analysis and inves-
tigated in a secondary analysis. The MMRM ap-
proach, by which the missing values with respect to
post-baseline primary outcomes are dealt with, dem-
onstrates favorable characteristics in terms of type I
error rate, power, and bias of estimates compared to
alternative methods dealing with missing values, such
as last-observation-carried-forward (LOCF) [98–100].
The first (global) hypothesis to be tested states that
the change in the IDS-C30 total score is equal in all three
treatment groups: H0: μI1 = μI2 = μTAU. This hypoth-
esis will be tested at a two-sided level of significance of
5% against the alternative, H1: μI1 ≠ μTAU or μI2 ≠
μTAU or μI1 ≠ μI2. If the first null hypothesis can be
rejected, the following three hypotheses for the two
group comparisons will be tested simultaneously. One
hypothesis to be tested states that the change in IDS-C30
total score between baseline (T2) and end of interven-
tion (T4) is equal for I-1 and TAU: H0I1: μI1 = μTAU.
This hypothesis will also be tested at a two-sided level of
significance of 5% against the alternative hypothesis,
H1I1: μI1 ≠ μTAU. A further hypothesis to be tested
states that the change in IDS-C30 total score between
baseline (T2) and end of intervention (T4) is equal for
I-2 and TAU: H0I2: μI2 = μTAU. This hypothesis will
again be tested at a two-sided level of significance of 5%
against the alternative hypothesis, H1I2: μI2 ≠ μTAU.
Another hypothesis to be tested states that the change in
IDS-C30 total score between baseline (T2) and end of
intervention (T4) is equal for I-1 and I-2: H0I3: μI1 =
μI2. This hypothesis will also be tested at a two-sided
level of significance of 5% against the alternative hypoth-
esis, H1I3: μI1 ≠ μI2. The treatment comparisons for
these three null hypotheses will be based on the con-
trasts between I-1 and TAU resp. I-2 and TAU resp. I-1
and I-2 at the end of the intervention (T4).
The above-described confirmatory approach control-
ling the type I error rate at 0.05 is pursued to enable
a proof of efficacy already in this pilot study (for
example, if the effect size is higher than anticipated).
If the effect size is d = 0.5 as assumed for sample
size calculation, the power to reject the null hypoth-
esis of no difference in the primary endpoint compar-
ing one novel intervention to TAU is only 70%
(instead of 80%) as planning was performed at the
more liberal level of 0.10.
Additional analyses
Descriptive methods will be used for the analysis of the
secondary outcomes, including the calculation of appro-
priate summary measures of the empirical distribution
(mean, standard deviation, median, minimum and
maximum for continuous variables, and frequency in
percentages for categorical variables) as well as calcula-
tion of descriptive two-sided p values. A special focus of
the exploratory analysis will be with respect to the time
course of the primary as well as the secondary
endpoints. Additionally, sensitivity analyses will be
conducted for different populations (PP population, ap-
propriate subgroups) and applying different imputation
techniques (such as LOCF) for missing values. Further
exploratory analyses will be performed to identify inter-
vention effects in subgroups and potential prognostic
factors (including hormone levels) for an intervention ef-
fect. Furthermore, variables possibly mediating treat-
ment effects such as reward processing, stress reactivity,
and compliance with the interventions will be explored.
Appropriate regression will be used following the four-
step procedure by Baron and Kenny [101]. Graphical
methods will be applied to visualize the findings of the
study. The safety analysis will be based on the set of all
randomized participants who were exposed to study
intervention at least once and includes calculation and
comparison of frequencies and rates of adverse and ser-
ious adverse events reported in the two intervention
groups. All analyses will be done using SAS version 9.4
or higher. A statistical analysis plan will be written be-
fore the final analysis.
Definition of analysis sets
Each participant’s allocation to the different analysis
populations (full analysis set according to the ITT
principle, PP analysis set, safety analysis set) will be de-
fined and in detail explained in the statistical analysis
plan which is finalized before the analysis. During the
data review, deviations from the protocol will be
assessed as “minor” or “major.” Major deviations from
the protocol will lead to the exclusion of a participant
from the PP analysis set.
Monitoring
The study will be monitored by the KKS Heidelberg, a
university-based institution which is independent from
other trial staff and very experienced in monitoring clin-
ical trials. Monitoring will be done by on-site and off-site
visits and frequent communication (letters, telephone,
facsimile, email) by a clinical monitor according to SOPs
of the KKS and the study-specific monitoring manual.
The monitor will ensure that the trial is conducted ac-
cording to the protocol and regulatory requirements by
review of source documents, entries into the CRFs, and
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essential documents. The monitor will document the
visits in a report for the PI as well as the local primary
investigator. The site will be provided with a follow-up
letter of the findings and the necessary actions to be
taken. As the monitoring strategy will consider current
aspects of risk-based quality management, frequency of
monitoring activities per site will vary depending on re-
cruitment, experience, and general performance, e.g.
quality of documentation of the individual trial sites. If
there are major findings during monitoring or an audit,
the investigational site might be closed by the trial co-
ordinator/PI.
In addition to the standardized monitoring procedures,
an independent DSMB has been established that
supervises the conduct of the trial and issues recommen-
dations for early termination, modifications, or continu-
ation of the trial, if necessary. The DSMB involves two
independent clinical experts and one biometrician for
monitoring the progress of the trial and ensure adher-
ence to protocol. The role of the DSMB will be to moni-
tor the progress of the trial and to ensure adherence to
protocol. The character of the interventions under inves-
tigation makes unexpected SAEs extremely unlikely. For
pragmatic reasons, complications recorded at predefined
visits, or notified by investigators, will be compiled and
reviewed annually. Actions will be taken if, halfway
through the trial, clear imbalances regarding the safety
of the participants become evident. Also, if evidence
from other studies becomes available that definitely
favors one or the other intervention and violates thera-
peutic uncertainty, DSMB members will decide if
recruitment needs to be stopped (for further informa-
tion, see [102]).
Ethics and dissemination
Before the first individual has been enrolled onto the
trial, all ethical and legal requirements were met. Study
protocol, participant information, and the respective
consent form were approved by the responsible ethical
committees before start of the trial. The study protocol
was first ethically reviewed and approved by the institu-
tional review board (IRB) of the Medical Faculty, Goethe
University, Frankfurt am Main, German (No. 353/16, 13
January 2017). Subsequent approval of this vote was
done by the ethical committee of Vall d’Hebron Re-
search Institute, Barcelona, Spain (No. PR(AG)105/2017,
19 April 2017), King’s College London, UK (No. 17/LO/
0958, 11 July 2017), and Radboud University Medical
Centre, Nijmegen, The Netherlands (No. 2017-3238, 5
October 2017). Any modifications to the protocol which
may impact on the conduct of the study, potential
benefit of the participant, or may affect participant
safety, including changes of study objectives, study
design, participant population, sample sizes, study
procedures, or significant administrative aspects, will re-
quire a formal amendment to the protocol. The IRB of
the PI, as well as the IRB of the participating centers and
trial registries will be informed of all subsequent proto-
col amendments which require approval in accordance
with local legal requirements.
The procedures set out in this trial protocol, pertain-
ing to the conduct, evaluation, and documentation of
this trial, are designed to ensure that all persons involved
in the trial abide by GCP (as far as applicable) and the
ethical principles described in the current revision of the
Declaration of Helsinki. The trial is carried out in keep-
ing with local legal and regulatory requirements, al-
though German Drug Law and Medical Device Law are
not applicable. Each site’s PI ensures that all persons
assisting with the trial are adequately informed about
the protocol, any amendments to the protocol, the trial
treatments, their trial-related duties, and functions. The
particular local investigator maintains a list of sub-
investigators and other appropriately qualified persons
to whom he or she has delegated significant trial-related
duties. Equally, each local primary investigator ensures
that the respective center is responsible for the correct
application of the therapy-manuals.
Before being enrolled in the clinical trial, the adoles-
cent’s caretaker(s) and the adolescent participant as well
as the young adult participant must consent to the par-
ticipation of the participant after the nature, scope, and
possible consequences of the clinical trial have been ex-
plained to them in an understandable oral and written
form. Participants as well as their caretakers can with-
draw from the study any time without giving a reason.
Informed consent will be obtained by the local investiga-
tor and stored in the ISF at each study site. A copy of
the signed informed consent document will be given to
the adolescent’s caretaker(s) and the young adult partici-
pant. The documents will be in a language understand-
able to the individual and his/her caretakers and specify
who informed him or her. For this reason, there are
three information documents in the presented study:
one for participating adolescents; one for the parents/
caretakers of the participating adolescents; and one for
young adults.
Throughout the trial, participants are pseudonymized.
Trial data stored on a computer will be stored in accord-
ance with the local data protection law and will be
handled in strictest confidence. Distribution of these
data to unauthorized persons is strictly prohibited. The
appropriate regulations of local data legislation will be
fulfilled in their entirety. Authorized persons (e.g.
clinical monitors, auditors) regularly inspect the
participant-related data collected during the trial ensur-
ing the data protection law (see monitoring). The local
primary investigator of each study site will maintain a
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personal participant identification list (participant num-
bers with the corresponding names) to enable records to
be identified.
The trial statistician as well as the PI, and, in case of
SAEs, members of the DMSB, have access to the final
trial set for statistical analyses. After the publication of
the primary and secondary outcome measures, all re-
sponsible investigators at all study sites will get access to
the data to be able to reanalyze the data with regard to
specific additional research questions. In case of an ex-
ternal request for replication, the respective statistical
analysis will be provided by the trial statistician.
Trial results will be reported to participants, health-
care professionals, the public, patient advocacy groups,
and other relevant groups via publications, conferences,
press releases, and public talks. Authorship eligibility
guidelines according to the International Committee of
Medical Journal Editors [103] will be adhered to. No
professional writers will be involved in any publication.
Discussion
We have presented a design and protocol for an RCT of
two non-pharmacological interventions—BLT and EI—for
the prevention of co-morbid depression and obesity in
adolescents and young adults with ADHD. This pilot
phase-IIa study will evaluate the feasibility and efficacy of
the two manualized ten-week interventions combined
with m-health based monitoring and reinforcement in this
young patient sample.
The PROUD trial has several strong points. It is the first
RCT on the use of two new non-pharmacological inter-
ventions implemented to directly target the prevention of
depression and obesity—two major co-morbidities of
adult ADHD. Existing studies primarily addressed the
effects of pharmacological and non-pharmacological treat-
ments on the core ADHD symptoms [14]. Given that co-
morbidity is a hallmark of adult ADHD [5], significantly
increasing disease burden [12], it is an important and
timely goal to develop effective treatments of major co-
morbidities as well. Moreover, to date no RCT has evalu-
ated the feasibility and efficacy of non-pharmacological
interventions that specifically target the prevention of co-
morbid conditions during the potentially sensitive phase
of adolescence and young adulthood when adherence to
pharmacological treatment is also typically low [27–29].
Physical exercise and BLT are two non-pharmacological
interventions which have been well established in the
treatment of depression in adults and adolescents [40–42,
68–71]. Recent evidence also suggests their efficacy in the
treatment of obesity [47, 48, 73]. Importantly, these treat-
ments were chosen because they are thought to directly
modulate two key pathophysiological mechanisms of
ADHD—namely a dysregulation of the dopaminergic [37]
and circadian systems [57, 58]—that potentially link
ADHD to co-morbid depression and obesity [38, 39, 59,
60]. Taking the neurobiological evidence into account, it
seems reasonable that these non-pharmacological treat-
ments might be specifically useful in the treatment and
prevention of depression and obesity in adolescents and
young adults with ADHD. However, systematic interven-
tions studies that target these co-morbid disorders of
ADHD are lacking. With regard to BLT, only one open-
label trial exists and reported positive effects on core
ADHD symptoms and co-morbid depressive symptoms in
adult patients with ADHD [75]. With regard to physical
exercise, preliminary findings in children with ADHD
point to its effectiveness mainly on core clinical ADHD
and cognitive symptoms [50]. Furthermore, according to
this systematic review [50], higher-quality intervention re-
search is needed including large sample sizes, adequate
control groups, observer-blinded assessments, and the use
of a wide variety of clinical, cognitive, behavioral, and
physical/(neuro)physiological outcome measures. The
PROUD study is a prospective RCT that fulfils rigorous
methodological requirements by including a large sample
of 219 participants at four study centers, a TAU control
condition, and observer-blinded assessment of the primary
outcome measure. This is a critical aspect because partici-
pants cannot be blinded with regard to the intervention.
Also, an automated online randomization procedure is
clearly defined and reflects the study design with respect
to the multicenter study and the group-based
randomization. The statistical analysis also takes the dif-
ferent study centers into account. A strong advantage of
this trial is the inclusion of several additional secondary
outcome measures to assess immediate as well as long-
term intervention effects on obesity (measured in terms of
several body composition parameters), ADHD-specific
symptoms, general psychopathological symptoms, health-
related quality of life, neurocognitive functions, chrono-
type, and body-related measures such as blood pressure
and heart rate, physical fitness, and concentrations of hor-
mones. In addition, variables possibly moderating or
mediating treatment effects will be explored.
The PROUD trial also bears substantial innovation po-
tential by making use of a mobile technology developed
specifically for this trial by the KIT. Both interventions will
be supported by the m-health application which has three
strong advantages. First, targeting adolescents and young
adults with BLT and EI implies specific problems, as this
age group usually has little motivation for lifestyle change.
The mobile technology is generally viewed very favorably
by this age group and therefore it is reasonable that the
app-based instruction reminders and reinforcement strat-
egies booster their motivation for change [54]. Second, the
sensor allows recording of relevant parameters such as
physical activity and light exposure throughout the study
phase which makes it possible to monitor compliance
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during the intervention. Third, the m-health system will
be used to assess physical activity, light exposure and
additional cognitive-emotional parameters (i.e. reward
processing and stress reactivity) online at home pre- and
post-intervention. These parameters will then be included
in the analyses as variables moderating or mediating the
treatment effects.
The manualized interventions, combining BLT and EI
with m-health-based monitoring and reinforcement to
increase the participant’s motivation and compliance are
easy to implement both for the clinicians and the partici-
pants. The interventions are portable, cost-effective, and
almost entirely free of side effects. Therefore, if the
PROUD trial can prove their feasibility and efficacy in
adolescents and young adults with ADHD, they have the
potential to act as adjuncts to treatment as usual or even
as primary treatments in the future.
In conclusion, the high risk for co-morbid depression
and obesity for adolescents with ADHD has been increas-
ingly recognized and guidelines for treatment and preven-
tion are urgently needed. The PROUD trial is a rigorous
designed RCT on m-health-based BLT and EI to provide
first insights into the feasibility and efficacy of these non-
pharmacological interventions to prevent co-morbid de-
pression and obesity in adolescents and young adults with
ADHD. If at least medium effects can be established with
regard to the prevention of depressive symptoms and
obesity, a larger scale confirmatory phase-III trial may be
warranted.
Additional files
Additional file 1: SPIRIT Checklist. (DOC 122 kb)
Additional file 2: Definition and handling of SAEs. SAEs are defined
and it is described how SAEs are assessed, reported, and monitored
within the PROUD trial. (DOCX 23 kb)
Additional file 3: Secondary outcome measures of the PROUD trial.
Detailed description of all secondary outcome measures that will be
assessed at baseline, directly after the intervention/continuing TAU (T4),
and/or at 12-week follow-up (T5). (DOCX 57 kb)
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